Oraya TherapyTM Stereotactic Radiotherapy for Wet AMD


Oraya Therapeutics’ AMD Radiotherapy Device Receives New Indication of Use for Choroidal Metastases
Extended CE Mark brings new treatment option to patients in the United Kingdom, Germany and Switzerland…Read Press Release >

Carl Zeiss Meditec and Oraya Therapeutics sign collaboration agreement

Read Zeiss Press Release >

Treatment Locations


Kent residents with wet age-related macular degeneration (AMD) now have access to the Oraya Therapy at the Kent Institute of Medicine and Surgery (KIMS) in Maidstone. The hospital has recently begun treating patients. The treatment is carried out by one of KIMS’ highly skilled team of ophthalmologists. For more information in the UK, call 0800-690-6495.


Three-year Data from INTREPID Study Shows Favorable Safety Profile — Commercial Adoption of Oraya Therapy Continues to Grow.

Full results of three-year safety follow-up data from the INTREPID study of Oraya Therapy™ for wet age-related macular degeneration (AMD) further demonstrated a favorable safety profile and also showed that there was no significant difference in vision outcomes in patients treated with Oraya Therapy compared with those receiving anti-vascular endothelial growth factor (anti-VEGF) injections alone.
More >

Special Event at House of Commons


Leading organizations and Members of Parliament come together at a special event sponsored by Oraya Therapeutics. More >

AMD Alliance International leads an event at the House of Commons addressing current issues with diagnosing, treating and managing the growing number of aging people affected by age-related macular degeneration (AMD), the leading cause of blindness in the western world.


Sir David Amess hosts a parliamentary event about age-related macular degeneration (AMD). More >

BBC Look North – September 2014


Press Release: First National Health Service hospital in UK and four prestigious hospitals in Germany adopt Oraya Therapy to maintain vision with reduced anti-VEGF injections.
More >

News-Medical.net – September 2014


Treating wet AMD with gold nanoparticles: an interview with Jim Taylor, CEO, Oraya Therapeutics. More >


Age-Related Macular Degeneration (AMD) is a progressive disease that causes loss of central vision leading to blindness. It is the primary cause of vision loss for seniors in the industrialized world. While there is no cure for AMD, the Oraya Therapy™ for Wet AMD is an exciting new treatment.   More >


Founded in 2007, Oraya® Therapeutics, Inc. is a privately held company developing an innovative and non-invasive therapy designed to advance the treatment options for wet AMD.  More >


Physicians and patients require a new option and a new vision for the treatment of wet AMD. Oraya Therapy— intended as a one-time, non-invasive procedure—uses a low-voltage, stereotactic approach. It delivers precisely controlled X-rays confined to the diseased area of interest, sparing the surrounding structures of the eye.  More >


Published Articles
Stereotactic Radiotherapy for Neovascular Age-Related Macular Degeneration: Year 2 Results of the INTREPID Study

Published in Ophthalmology, January 2015.
Free Download >

Stereotatic Radiotherapy for Wet Age-Related Macular Degeneration (INTREPID): Influence of Baseline Characteristics on Clinical Response

Published ahead of print, RETINA, August 2014. Download >

Treating Neovascular AMD

Published in Expert Reviews of Ophthalmology, 2014. Download >

INTREPID Study One Year Results

Published in Ophthalmology, September 2013. Download >

© 2015 All rights reserved. Oraya Therapeutics, Inc. The IRay® is a CE-marked medical device. The IRay is not available for sale in the United States. For additional details, including safety and risk information, please see the ORAYA THERAPY section of this website. Oraya, Oraya Therapy, IRay and I-Guide are either trademarks or registered trademarks of Oraya Therapeutics, Inc. in the United States and other countries.